PMID- 35957839
OWN - NLM
STAT- MEDLINE
DCOM- 20220815
LR  - 20220825
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - A Big Role for microRNAs in Gestational Diabetes Mellitus.
PG  - 892587
LID - 10.3389/fendo.2022.892587 [doi]
LID - 892587
AB  - Maternal diabetes is associated with pregnancy complications and poses a serious 
      health risk to both mother and child. Growing evidence suggests that pregnancy 
      complications are more frequent and severe in pregnant women with pregestational 
      type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) compared to 
      women with gestational diabetes mellitus (GDM). Elucidating the 
      pathophysiological mechanisms that underlie the different types of maternal 
      diabetes may lead to targeted strategies to prevent or reduce pregnancy 
      complications. In recent years, microRNAs (miRNAs), one of the most common 
      epigenetic mechanisms, have emerged as key players in the pathophysiology of 
      pregnancy-related disorders including diabetes. This review aims to provide an 
      update on the status of miRNA profiling in pregnancies complicated by maternal 
      diabetes. Four databases, Pubmed, Web of Science, EBSCOhost, and Scopus were 
      searched to identify studies that profiled miRNAs during maternal diabetes. A 
      total of 1800 articles were identified, of which 53 are included in this review. 
      All studies profiled miRNAs during GDM, with no studies on miRNA profiling during 
      pregestational T1DM and T2DM identified. Studies on GDM were mainly focused on 
      the potential of miRNAs to serve as predictive or diagnostic biomarkers. This 
      review highlights the lack of miRNA profiling in pregnancies complicated by T1DM 
      and T2DM and identifies the need for miRNA profiling in all types of maternal 
      diabetes. Such studies could contribute to our understanding of the mechanisms 
      that link maternal diabetes type with pregnancy complications.
CI  - Copyright (c) 2022 Masete, Dias, Malaza, Adam and Pheiffer.
FAU - Masete, Matladi
AU  - Masete M
AD  - Biomedical Research and Innovation Platform, South African Medical Research 
      Council, Cape Town, South Africa.
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University 
      of Pretoria, Pretoria, South Africa.
FAU - Dias, Stephanie
AU  - Dias S
AD  - Biomedical Research and Innovation Platform, South African Medical Research 
      Council, Cape Town, South Africa.
FAU - Malaza, Nompumelelo
AU  - Malaza N
AD  - Biomedical Research and Innovation Platform, South African Medical Research 
      Council, Cape Town, South Africa.
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University 
      of Pretoria, Pretoria, South Africa.
FAU - Adam, Sumaiya
AU  - Adam S
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University 
      of Pretoria, Pretoria, South Africa.
FAU - Pheiffer, Carmen
AU  - Pheiffer C
AD  - Biomedical Research and Innovation Platform, South African Medical Research 
      Council, Cape Town, South Africa.
AD  - Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University 
      of Pretoria, Pretoria, South Africa.
AD  - Center for Cardio-Metabolic Research in Africa (CARMA), Division of Medical 
      Physiology, Faculty of Health Sciences, Stellenbosch University, Cape Town, South 
      Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220725
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (MicroRNAs)
SB  - IM
MH  - *Diabetes Mellitus, Type 1/genetics
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - *Diabetes, Gestational/genetics
MH  - Female
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - Pregnancy
MH  - *Pregnancy Complications
PMC - PMC9357936
OTO - NOTNLM
OT  - gestational diabetes mellitus
OT  - microRNAs
OT  - pregnancy
OT  - type 1 diabetes mellitus
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/13 06:00
MHDA- 2022/08/16 06:00
PMCR- 2022/01/01
CRDT- 2022/08/12 02:46
PHST- 2022/03/09 00:00 [received]
PHST- 2022/06/24 00:00 [accepted]
PHST- 2022/08/12 02:46 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/16 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.892587 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jul 25;13:892587. doi: 
      10.3389/fendo.2022.892587. eCollection 2022.